The $425K-a-Year Kidney Drug That Just Got the Green Light
The FDA just approved a $425,000-a-year kidney disease drug from a company that didn't even exist under its current name five years ago. TRUTAKNA's accelerated approval is only half the story; the data that could make or break it arrives in weeks.
A Disease That Picks on the Young
Imagine being 25, feeling perfectly healthy, and then learning your kidneys are slowly destroying themselves. That's the reality for many people diagnosed with IgA nephropathy (IgAN), a chronic kidney disease where the body's own immune system deposits harmful proteins in the kidneys. It's the most common form of primary glomerulonephritis (kidney inflammation caused by immune attack), and it has a nasty habit of showing up in adolescents and young adults.
For decades, doctors could only offer these patients blood pressure meds and a shrug. About 27% of patients reach kidney failure or lose half their kidney function within 10 years. Some estimates suggest up to half will need dialysis or a transplant over their lifetimes.
That backdrop makes this week's news matter. On July 7, 2026, the FDA granted accelerated approval to TRUTAKNA (atacicept), a new biologic from Vera Therapeutics, for adults with IgAN at risk of disease progression. It's Vera's first-ever commercial product, and it carries a price tag of roughly $425,000 per year.
What TRUTAKNA Actually Does
To understand why this drug is interesting, you need a 30-second crash course on what goes wrong in IgAN.
Think of your immune system as a factory that makes different types of antibodies. In IgAN, the factory produces a defective version of one antibody called IgA1. These defective antibodies clump together, travel to the kidneys, and cause inflammation that slowly scars the tissue. Two proteins, called BAFF and APRIL, act like foremen at the factory; they keep the production line running hot.
TRUTAKNA works by blocking both BAFF and APRIL at the same time. Shut down the foremen, slow the factory, reduce the damage. It's a dual-target approach that sets it apart from some competitors that only hit one of those proteins.
Patients inject the drug at home once a week using an autoinjector (think: EpiPen-style). No infusion centers, no IV lines. That convenience factor is a big deal for a disease that requires long-term treatment.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Data Behind the Approval
The FDA based its decision on the ORIGIN Phase 3 trial, a global, randomized, placebo-controlled study in patients with biopsy-proven IgAN who still had significant protein leaking into their urine despite being on standard blood pressure medications.
The primary goal was straightforward: reduce proteinuria (protein in the urine, a key marker of kidney damage). At 36 weeks, atacicept delivered a 46% reduction from baseline in urine protein levels. Compared to placebo, the gap was 42%, with a p-value below 0.0001. In clinical trial language, that's about as clean a win as you can get.
Those numbers also represent a meaningful step up from the earlier Phase 2b trial, which showed a 34% reduction from baseline and a 35% gap versus placebo at the same time point.
Critically, the safety profile looked almost identical to placebo across both studies. No new safety red flags emerged. For a disease where older treatments like systemic steroids can cause diabetes, infections, and bone loss, a drug that works without wrecking other systems is a welcome change.
The "Accelerated" Asterisk
Before anyone pops champagne, there's a catch worth understanding. This is an accelerated approval, which means the FDA said yes based on a surrogate endpoint (proteinuria reduction) rather than proof that the drug actually prevents kidney failure long-term. It's like getting into college on a conditional acceptance: you still need to show up and pass your classes.
Vera's ORIGIN 3 trial is still running in blinded fashion, collecting data on eGFR (estimated glomerular filtration rate, essentially a measure of how well the kidneys filter blood). Results on that key secondary endpoint are expected in Q3 2026. If the kidney function data look strong, Vera can pursue full approval, likely in 2027.
If the data disappoint? The FDA could narrow, modify, or even pull the label. That's the regulatory tightrope every accelerated approval walks.
A Crowded (and Expensive) Neighborhood
Vera isn't entering an empty market. IgAN has gone from a therapeutic wasteland to one of nephrology's hottest battlegrounds in just a few years.
Nefecon (targeted-release budesonide) was the first IgAN-specific therapy approved in the U.S. back in 2021. Filspari (sparsentan) followed as a non-immunosuppressive option. Then came iptacopan, a complement inhibitor, and more recently atrasentan and sibeprenlimab, each hitting different parts of the disease pathway.
So TRUTAKNA is entering a market with at least five other disease-targeted therapies. That sounds daunting, but the addressable population is large: roughly 200,000 Americans live with IgAN according to recent claims-based estimates. Many still have poorly controlled disease. And the multi-hit biology of IgAN means different patients may respond better to different mechanisms, giving doctors reasons to try each drug.
The price, though, will draw scrutiny. At $32,700 for every 28-day supply, TRUTAKNA is firmly in the specialty biologic tier. Payers will want to see the eGFR data before loosening the purse strings for broad coverage.
What Wall Street Thinks
Analysts were already bullish heading into the approval. LifeSci Capital carried a Buy rating with a target of $70.
The approval itself was widely expected, so the real catalyst isn't the green light; it's the Q3 2026 eGFR readout. Positive kidney function data would convert the conditional approval into a durable franchise, strengthen reimbursement negotiations, and likely push analyst models higher. A miss would do the opposite, fast.
The Bigger Picture
Vera Therapeutics was founded in 2016 as a gene repair company with a completely different name (Trucode Gene Repair, Inc.). It pivoted, rebranded in 2020, went public in 2021 at $11 a share, and now has its first drug on the market. That's a remarkable arc for a still-young biotech company.
For patients, TRUTAKNA offers something genuinely meaningful: a targeted, well-tolerated, self-administered therapy for a disease that used to have almost no good options. The dual BAFF/APRIL mechanism is scientifically elegant, and the home-use convenience matters for patients facing years of treatment.
But the story is only half-written. The accelerated approval is the first act. The eGFR data coming in Q3 will determine whether TRUTAKNA becomes a blockbuster or a cautionary tale about surrogate endpoints. For Vera, for investors, and most importantly for the roughly 200,000 Americans with IgAN, the next few months are everything.
4 min read
BMS Is Printing Money Right Now. The Clock Is Ticking.
Bristol Myers Squibb just crushed Q2 estimates and hiked its 2026 forecast by billions, thanks to a blood thinner that won't quit and a new drug lineup firing on all cylinders. There's just one problem: the biggest patent cliff in pharma history is about 18 months away.
